RedHill Biopharma Sells Talicia to Apotex for $18M Upfront Plus $35M in Potential Milestones

RedHill Biopharma Sells Talicia to Apotex for $18M Upfront Plus $35M in Potential Milestones →

RedHill Biopharma Ltd. (Nasdaq: RDHL, FinanceWire reference: FNEWS) has finalized the sale of its Talicia gastrointestinal franchise to a subsidiary of Apotex Health Corp. (TSX: APTX) for an $18 million upfront cash payment, with additional…